EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn’s Disease: Results from the Japanese CONFIDE Study

Toshifumi Hibi iD, Taku Kobayashi iD, Masaru Tanaka iD, Satoshi Osaga iD, Alison J Potts Bleakman iD, Theresa Hunter Gibble iD, Marijana Nedeljkovic Protic iD, Isabel Redondo iD, Koji Matsuo iD, Tadakazu Hisamatsu iD

Advances in Therapy · 2025

DOI: 10.1007/s12325-024-03078-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advances in Therapy, 2025. Verfasst von Toshifumi Hibi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Minato, Tokyo, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Cost of Illness, Quality of Life. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The global Communicating Needs and Features of Inflammatory Bowel Disease Experiences (CONFIDE) study aimed to evaluate the impact of ulcerative colitis (UC)- and Crohn's disease (CD)-related symptoms on patients' lives and elucidate communication gaps between patients and health care professionals (HCPs). We report the findings from the study in patients with UC or CD and HCPs in Japan. METHODS: Online, quantitative, cross-sectional surveys were conducted in Japan for patients with moderate-to-severe UC or CD and HCPs responsible for the care of patients with UC and/or CD. Subgroup analyses based on disease activity were conducted using the Manitoba Inflammatory Bowel Disease Index. Data were described using descriptive statistics. RESULTS: Surveys were completed by 124 patients with UC, 99 patients with CD, and 100 HCPs in Japan. Differences were noted in the most common patient-reported symptoms experienced in the month prior to survey completion between patients with UC and CD (diarrhea [45.2% UC, 68.7% CD], flatulence [34.7% UC, 32.3% CD], increased stool frequency [32.3% UC, 43.4% CD], bowel urgency [BU; 25.0% UC, 32.3% CD], and fatigue [36.4% CD]). More patients with active disease than inactive disease reported these symptoms. BU and BU-related accidents were among the symptoms ranked as most impactful by patients with UC and CD. HCP-perceived symptoms with the greatest impact on patients were diarrhea and blood in stool. Findings in the Japanese cohort of CONFIDE were generally consistent with those in the United States (US)/European cohorts. The percentage of patients reporting BU as the symptom with the greatest impact was higher in the US/European cohorts than in the Japanese cohort, potentially as a result of differences in baseline characteristics and social environments such as toilet facilities. CONCLUSION: BU is an impactful symptom among Japanese patients with UC and CD and should be considered by HCPs during treatment of these conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeCrohn DiseaseCost of IllnessQuality of LifeHumansMaleFemaleJapanCross-Sectional StudiesAdultMiddle AgedAgedSurveys and QuestionnairesHealth PersonnelYoung AdultSeverity of Illness IndexActivities of Daily LivingEast Asian People

Stichwörter der Autor:innen

Bowel urgencyCrohn’s diseaseJapanQuality of lifeSymptom burdenUlcerative colitis

Autor:innen und Institutionen

  • Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Minato, Tokyo, Japan.
  • Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., 5-1-28, Isogami-Dori, Chuo-Ku, Kobe, Hyogo, 651-0086, Japan. tanaka_masaru@lilly.com.
  • Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., 5-1-28, Isogami-Dori, Chuo-Ku, Kobe, Hyogo, 651-0086, Japan.
  • Eli Lilly and Company, Indianapolis, IN, USA.
  • Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Mitaka, Tokyo, Japan.

ORCID-Profile: Toshifumi Hibi, Taku Kobayashi, Masaru Tanaka, Satoshi Osaga, Alison J Potts Bleakman, Theresa Hunter Gibble, Marijana Nedeljkovic Protic, Isabel Redondo, Koji Matsuo, Tadakazu Hisamatsu

Förderung

  • Eli Lilly and Company

Zitieren

APA

Hibi, T., Kobayashi, T., Tanaka, M., Osaga, S., Potts Bleakman, A. J., Hunter Gibble, T., Nedeljkovic Protic, M., Redondo, I., Matsuo, K., & Hisamatsu, T. (2025). Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn’s Disease: Results from the Japanese CONFIDE Study. Advances in Therapy. https://doi.org/10.1007/s12325-024-03078-3

Vancouver

Hibi T, Kobayashi T, Tanaka M, Osaga S, Potts Bleakman AJ, Hunter Gibble T, et al. Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn’s Disease: Results from the Japanese CONFIDE Study. Advances in Therapy. 2025. doi:10.1007/s12325-024-03078-3

BibTeX
@article{Hibi2025,
  author = {Hibi, Toshifumi and Kobayashi, Taku and Tanaka, Masaru and Osaga, Satoshi and Potts Bleakman, Alison J and Hunter Gibble, Theresa and Nedeljkovic Protic, Marijana and Redondo, Isabel and Matsuo, Koji and Hisamatsu, Tadakazu},
  title = {Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn’s Disease: Results from the Japanese CONFIDE Study},
  journal = {Advances in Therapy},
  year = {2025},
  doi = {10.1007/s12325-024-03078-3}
}
Kostenlos starten →